A
APUS
vs
S&P 500
S&P 500
Over the past 12 months, APUS has underperformed S&P 500, delivering a return of -13% compared to the S&P 500's +13% growth.
Stocks Performance
APUS vs S&P 500
Performance Gap
APUS vs S&P 500
Performance By Year
APUS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Apimeds Pharmaceuticals US Inc
Glance View
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
